Free Trial
NASDAQ:BIAF

bioAffinity Technologies Q4 2023 Earnings Report

bioAffinity Technologies logo
$0.29 -0.02 (-7.38%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$0.29 +0.00 (+0.14%)
As of 08/1/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

bioAffinity Technologies EPS Results

Actual EPS
-$0.26
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

bioAffinity Technologies Revenue Results

Actual Revenue
$2.21 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

bioAffinity Technologies Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Monday, April 1, 2024
Conference Call Time
12:30PM ET

Upcoming Earnings

bioAffinity Technologies' Q2 2025 earnings is scheduled for Wednesday, August 13, 2025, with a conference call scheduled on Thursday, August 14, 2025 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

bioAffinity Technologies Earnings Headlines

Market Crash Warning: How to Protect Your Wealth Before August 12th
New China tariffs hit August 12th—and Wall Street’s already moving. Banks and billionaires are quietly shifting out of stocks, while everyday investors remain exposed. A free guide reveals where the smart money is going—and how to protect your wealth before the next sell-off.
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF), a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

View bioAffinity Technologies Profile

More Earnings Resources from MarketBeat